Search results
Results from the WOW.Com Content Network
Its price in the U.S. is $2.2 million. Its total addressable market includes about 35,000 patients in the U.S. and Europe and an additional 23,000 in Saudi Arabia and Bahrain, where it is also ...
CRISPR Therapeutics is a mid-cap biotech company founded in 2013. It develops gene-editing medicines using CRISPR/Cas9, a technique created by scientists who, as a result of their work, received a ...
Casgevy, at a price of $2.2 million in the U.S. -- and very little competition to speak of, at least for now -- could easily vastly exceed the $1 billion in sales milestone. ... Before you buy ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
The stock of CRISPR Therapeutics AG (NAS:CRSP, 30-year Financials) is estimated to be significantly overvalued, according to GuruFocus Value calculation.